BioNTech SE (NASDAQ: BNTX) reports Q3 FY21 revenues of €6.08 billion compared to €67.5 million a year ago, mainly due to rapid increases in the supply and sales of the COVID-19 vaccine worldwide. As of November 2, BioNTech and its partner Pfizer Inc (NYSE: PFE) have shipped over two billion doses of its COVID-19 vaccine (BNT162b2). BioNTech generated an operating income of €4.7 billion, a ...Full story available on Benzinga.com
